
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is a leader in the continuous glucose monitoring (CGM) industry, and its recent clinical trial results and data support its expanding presence in the diabetic market, including in the large Type 2 non-insulin population. With high adherence rates and positive outcomes across various treatment regimens, DexCom's CGMs offer a complementary tool for Type 2 patients, positioning the company well as CMS expands coverage for this population. Along with solid financial metrics and a strong pipeline of innovation, DexCom presents a sustainable mid-teens revenue growth story with the potential for significant upside in the years to come.
Bears say
DexCom is facing strong competition in the T2NIT market and may not be able to maintain its share against companies such as Abbott Laboratories. Additionally, the lack of traditional financial metrics makes it difficult to determine a price target for the stock. The recent preliminary WW revenue of $1.260B and EPS of $0.68 may suggest a strong financial performance, but GM of 63.5% and a lower tax rate may mask potential weaknesses. The company is also heavily reliant on potential changes in the coverage landscape and may face setbacks in its efforts to secure Medicare coverage, despite optimistic commentary from management.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares